Taysha doses first patient with TSHA-102 in Phase 1/2 REVEAL trial for Rett syndrome

Taysha Gene Therapies, Inc.

First adult patient received TSHA-102, an AAV9 gene therapy using miRARE technology to regulate MECP2.
Phase 1/2 REVEAL trial: open-label, dose-escalation (5x10^14 vg then 1x10^15 vg) and dose-expansion in adult females.
Initial safety data from first patient expected at R&D Day on June 28, 2023.
Study conducted at CHU Sainte-Justine in Montreal, Canada; independent data monitoring committee will review safety at ~6 weeks.
First time a gene therapy is evaluated clinically for Rett syndrome, per Taysha management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.